================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
December 15, 2004
Date of Report (Date of earliest event reported)
COMPETITIVE TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-8696 36-2664428
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
1960 Bronson Road, Fairfield, Connecticut 06824
(Address of principal executive offices) (Zip Code)
(203) 255-6044
(Registrant's telephone number, including area code)
__________________
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01 Other Events.
On December 16, 2004, Competitive Technologies, Inc. ("CTT") announced that
a license had been granted to Abbott Laboratories ("Abbott") under CTT's U.S.
Patent Number 4,940,658 for homocysteine assays. The granting of the license
settled previously filed litigation between CTT and Abbott.
Pursuant to the license Abbott will pay a license fee and royalties on
sales of Abbott homocysteine assays. The license will relieve Abbott customers
from their obligation to pay royalties on results obtained using the Abbott
assay by virtue of the royalty paid by Abbott to CTT. CTT's share of the license
fee (that will be paid in January 2005) will be $5.2 million. The license also
releases Abbott's customers of any obligation to pay royalties to CTT for
homocysteine test results obtained using Abbott assays in the past, but does not
entitle them to any refund of any royalties previously paid to CTT.
A copy of the press release is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits.
Exhibit No. Description
----------- -----------------------------------------------------
Exhibit 99.1 Press release dated December 16, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
COMPETITIVE TECHNOLOGIES, INC.
Date: December 20, 2004 By: /s/ John B. Nano
----------------
Name: John B. Nano
Title: President and
Chief Executive Officer
EXHIBIT INDEX
Exhibit No. Description
------------ -------------------------------------------------------------
Exhibit 99.1 Press release dated December 16, 2004 announcing that CTT had
granted a license to Abbott Laboratories for homocysteine
assays.